MyChesCo on MSN1d
Ocugen’s OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa TreatmentOcugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of its gene-agnostic therapy, OCU400, as the European Commission has delivered a positive opinion designating it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback